PMID- 37474877
OWN - NLM
STAT- MEDLINE
DCOM- 20240130
LR  - 20240206
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 33
IP  - 1
DP  - 2024 Jan
TI  - Effectiveness and safety of secukinumab in Chinese patients with moderate to 
      severe plaque psoriasis in real-world practice.
PG  - e14890
LID - 10.1111/exd.14890 [doi]
AB  - A number of randomized controlled trials and real-world studies have demonstrated 
      the effectiveness and safety of secukinumab in the treatment of moderate to 
      severe psoriasis, whereas data on a large cohort of Chinese patients in long-term 
      real-world practice are limited. This was a single-centre, uncontrolled, 
      single-arm, prospective, observational cohort study that included 254 psoriatic 
      patients treated with secukinumab between September 2019 and December 2022. 
      Demographic and clinical characteristics of patients, clinical response and 
      adverse events were evaluated. The 75% improvement in Psoriasis Area and Severity 
      Index score (PASI 75), PASI 90, and PASI 100 in the 300 mg secukinumab group at 
      12 weeks were 91.7%, 74.0% and 39.7% respectively, increasing to 94.5%, 74.5% and 
      47.6% at 52 weeks. High body mass index (BMI), previous exposure to biologic 
      therapies and history of previous conventional systemic therapies were associated 
      with lower rates of PASI response. During the study period, 68 patients reported 
      83 adverse events (AEs) and the most frequent AEs were eczematous lesions. Up to 
      14.5% patients withdrew treatment due to disease remission combined with 
      inconvenient transportation during the COVID-19 pandemic at 52 weeks. The rate of 
      psoriasis exacerbation after COVID-19 infection in patients treated with 
      secukinumab was 24.3% (17/70). This real-world study confirmed the high 
      effectiveness of secukinumab in Chinese patients with moderate to severe plaque 
      psoriasis, with an acceptable safety profile.
CI  - (c) 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Liu, Yanhua
AU  - Liu Y
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Chu, Mengyang
AU  - Chu M
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Liu, Huan
AU  - Liu H
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Liu, Qian
AU  - Liu Q
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Wang, Rui
AU  - Wang R
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Shao, Shuai
AU  - Shao S
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Wang, Gang
AU  - Wang G
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
FAU - Yu, Chen
AU  - Yu C
AUID- ORCID: 0000-0001-7387-1198
AD  - Department of Dermatology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, P. R. China.
LA  - eng
GR  - 82003342/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Observational Study
DEP - 20230720
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - DLG4EML025 (secukinumab)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Antibodies, Monoclonal/adverse effects
MH  - Prospective Studies
MH  - Pandemics
MH  - Treatment Outcome
MH  - Severity of Illness Index
MH  - *Psoriasis/pathology
MH  - China
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - effectiveness
OT  - psoriasis
OT  - real-world
OT  - safety
OT  - secukinumab
EDAT- 2023/07/21 01:11
MHDA- 2024/01/30 12:44
CRDT- 2023/07/20 23:37
PHST- 2023/06/19 00:00 [revised]
PHST- 2023/03/30 00:00 [received]
PHST- 2023/07/09 00:00 [accepted]
PHST- 2024/01/30 12:44 [medline]
PHST- 2023/07/21 01:11 [pubmed]
PHST- 2023/07/20 23:37 [entrez]
AID - 10.1111/exd.14890 [doi]
PST - ppublish
SO  - Exp Dermatol. 2024 Jan;33(1):e14890. doi: 10.1111/exd.14890. Epub 2023 Jul 20.